Partnership to advance EEG biomarkers, tech to be used in pending phase 2 MDD study

A biotechnology company has announced a partnership with a precision biomedicine firm to advance the use of electroencephalogram biomarkers across its clinical pipeline in neuropsychiatry and cognition.
According to a press release from Gate Neurosciences, its collaboration with Beacon Biosignals will first involve utilization of Beacon’s FDA-cleared Dreem 3S headband device and neurobiomarker platform to conduct exploratory EEG and sleep analyses in those with major depressive disorder enrolled in Gate’s pending phase 2 trial of zelquistinel, slated to initiate by the middle of

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart